1. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. (12th December 2012) Authors: Shihab, Fuad S.; Cibrik, Diane; Chan, Laurence; Kim, Yu Seun; Carmellini, Mario; Walker, Rowan; Zibari, Gazi; Pattison, James; Cornu‐Artis, Catherine; Wang, Zailong; Tedesco‐Silva Jr, Helio Journal: Clinical transplantation Issue: Volume 27:Number 2(2013:Mar./Apr.) Page Start: 217 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cardiovascular Parameters to 2 years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy: An Analysis of the Randomized ELEVATE Study. Issue 10 (October 2017) Authors: Holdaas, Hallvard; de Fijter, Johan W.; Cruzado, Josep M.; Massari, Pablo; Nashan, Björn; Kanellis, John; Witzke, Oliver; Gutierrez-Dalmau, Alex; Turkmen, Aydin; Wang, Zailong; Lopez, Patricia; Bernhardt, Peter; Kochuparampil, Jossy; van der Giet, Markus; Murbraech, Klaus Journal: Transplantation Issue: Volume 101:Issue 10(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Issue 2 (15th December 2021) Authors: Kristensen, Lars Erik; Keiserman, Mauro; Papp, Kim; McCasland, Leslie; White, Douglas; Lu, Wenjing; Wang, Zailong; Soliman, Ahmed M; Eldred, Ann; Barcomb, Lisa; Behrens, Frank Journal: Annals of the rheumatic diseases Issue: Volume 81:Issue 2(2022) Page Start: 225 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Issue 3 (23rd November 2021) Authors: Östör, Andrew; Van den Bosch, Filip; Papp, Kim; Asnal, Cecilia; Blanco, Ricardo; Aelion, Jacob; Alperovich, Gabriela; Lu, Wenjing; Wang, Zailong; Soliman, Ahmed M; Eldred, Ann; Barcomb, Lisa; Kivitz, Alan Journal: Annals of the rheumatic diseases Issue: Volume 81:Issue 3(2022) Page Start: 351 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2. Issue 2 (14th June 2022) Authors: Ostor, Andrew J K; Soliman, Ahmed M; Papp, Kim A; Padilla, Byron; Wang, Zailong; Eldred, Ann; de Vlam, Kurt; Kivitz, Alan Journal: RMD open Issue: Volume 8:Issue 2(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial. (June 2022) Authors: Fleischmann, Roy; Friedman, Alan; Drescher, Edit; Singhal, Atul; Cortes-Maisonet, Gregorio; Doan, Thao; Lu, Wenjing; Wang, Zailong; Nader, Ahmed; Housley, William; Cohen, Stanley; Taylor, Peter C; Blanco, Ricardo Journal: Lancet Issue: Volume 4:Number 6(2022) Page Start: e395 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Secukinumab for Long‐Term Treatment of Psoriatic Arthritis: A Two‐Year Followup From a Phase III, Randomized, Double‐Blind Placebo‐Controlled Study. Issue 3 (25th February 2017) Authors: Kavanaugh, Arthur; Mease, Philip J.; Reimold, Andreas M.; Tahir, Hasan; Rech, Jürgen; Hall, Stephen; Geusens, Piet; Wang, Zailong; Pricop, Luminita; Mpofu, Shephard Journal: Arthritis care & research Issue: Volume 69:Issue 3(2017:Mar.) Page Start: 347 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Secukinumab for Long‐Term Treatment of Psoriatic Arthritis: A Two‐Year Followup From a Phase III, Randomized, Double‐Blind Placebo‐Controlled Study. Issue 3 (March 2017) Authors: Kavanaugh, Arthur; Mease, Philip J.; Reimold, Andreas M.; Tahir, Hasan; Rech, Jürgen; Hall, Stephen; Geusens, Piet; Wang, Zailong; Pricop, Luminita; Mpofu, Shephard Journal: Arthritis care & research Issue: Volume 69:Issue 3(2017:Mar.) Page Start: 347 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗